Literature DB >> 29540578

Decay of the Stress-Induced Ligand MICA Is Controlled by the Expression of an Alternative 3' Untranslated Region.

Tirtsah Toledano1, Alon Vitenshtein1, Noam Stern-Ginossar2, Einat Seidel1, Ofer Mandelboim3.   

Abstract

Recognition of the human stress-induced ligand MHC class I polypeptide-related sequence A (MICA) by the receptor NKG2D expressed on NK cells leads to NK cell-mediated killing of the target cells. Hence, the expression of MICA must be tightly regulated, and its cell surface expression needs to be quickly downregulated to avoid inappropriate activation of immune cells. In this article, we describe a transcript variant of human MICA that has not yet been studied, which contains a 3' untranslated region of 119 nt instead of 174. We identify its polyadenylation signal and demonstrate that, upon stresses, such as heat shock, butyrate treatment, and some oxidative and DNA-damaging treatments, the balance between the two MICA variants changes in favor of the less stable, longer variant. Mechanistically, we showed that this change is linked to microRNA activity and that poly-ADP ribose polymerase 1 is involved in the induction of the longer variant following stress. Thus, to our knowledge, we identify the first regulatory mechanism of a stress ligand's decay and also provide one of the first physiological examples for the biological function of a longer 3' untranslated region of a particular gene.
Copyright © 2018 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29540578     DOI: 10.4049/jimmunol.1700968

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  2 in total

1.  BCL11B regulates MICA/B-mediated immune response by acting as a competitive endogenous RNA.

Authors:  Mengyao Qian; Jingwen Geng; Kaili Luo; Zheng Huang; Qinkai Zhang; Jian-An Zhang; Liying Ji; Jianmin Wu
Journal:  Oncogene       Date:  2019-10-31       Impact factor: 8.756

Review 2.  NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy.

Authors:  Dominik Schmiedel; Ofer Mandelboim
Journal:  Front Immunol       Date:  2018-09-11       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.